MA39767B1 - Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'œil sec - Google Patents

Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'œil sec

Info

Publication number
MA39767B1
MA39767B1 MA39767A MA39767A MA39767B1 MA 39767 B1 MA39767 B1 MA 39767B1 MA 39767 A MA39767 A MA 39767A MA 39767 A MA39767 A MA 39767A MA 39767 B1 MA39767 B1 MA 39767B1
Authority
MA
Morocco
Prior art keywords
dry eye
aqueous solution
eye syndrome
treatment method
ophthalmic aqueous
Prior art date
Application number
MA39767A
Other languages
English (en)
Other versions
MA39767A (fr
Inventor
Martin Prinz
Original Assignee
Croma Pharma Ges M B H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50693490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39767(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Croma Pharma Ges M B H filed Critical Croma Pharma Ges M B H
Publication of MA39767A publication Critical patent/MA39767A/fr
Publication of MA39767B1 publication Critical patent/MA39767B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D65/00—Wrappers or flexible covers; Packaging materials of special type or form
    • B65D65/38—Packaging materials of special type or form
    • B65D65/40—Applications of laminates for particular packaging purposes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mechanical Engineering (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La présente invention concerne une solution aqueuse ophtalmique stérile comprenant d'environ 0,05 % à environ 0,5 % (poids/poids) de n-(n-acétylcystéinyl-)chitosane ou un sel pharmaceutiquement acceptable de celui-ci dans une solution d'excipient, le n-(n-acétylcystéinyl-)chitosane présentant une teneur en groupes thiol libres en proportion allant de 80 µmol/g de polymère à 280 µmol/g de polymère. L'invention concerne également un récipient contenant ladite solution ophtalmique ainsi que l'utilisation de celui-ci dans la prévention ou le traitement du syndrome de l'œil sec ou des signes et/ou des symptômes de l'œil sec.
MA39767A 2014-05-07 2015-05-04 Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'œil sec MA39767B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14167381 2014-05-07
EP15718956.4A EP3139903B1 (fr) 2014-05-07 2015-05-04 Solution ophtalmique aqueuse et procédé pour traiter le syndrome de l'oeil sec
PCT/EP2015/059674 WO2015169728A1 (fr) 2014-05-07 2015-05-04 Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'œil sec

Publications (2)

Publication Number Publication Date
MA39767A MA39767A (fr) 2015-11-12
MA39767B1 true MA39767B1 (fr) 2019-10-31

Family

ID=50693490

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39767A MA39767B1 (fr) 2014-05-07 2015-05-04 Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'œil sec

Country Status (28)

Country Link
US (2) US10342759B2 (fr)
EP (1) EP3139903B1 (fr)
JP (1) JP6639480B2 (fr)
KR (1) KR102378391B1 (fr)
CN (1) CN106456536B (fr)
AR (1) AR100334A1 (fr)
AU (1) AU2015257874B2 (fr)
BR (1) BR112016024454B1 (fr)
CA (1) CA2947065C (fr)
CL (1) CL2016002815A1 (fr)
CY (1) CY1122122T1 (fr)
DK (1) DK3139903T3 (fr)
ES (1) ES2747808T3 (fr)
HR (1) HRP20191667T1 (fr)
HU (1) HUE046425T2 (fr)
IL (1) IL248804B (fr)
LT (1) LT3139903T (fr)
MA (1) MA39767B1 (fr)
ME (1) ME03505B (fr)
MX (1) MX377727B (fr)
PL (1) PL3139903T3 (fr)
PT (1) PT3139903T (fr)
RS (1) RS59383B1 (fr)
RU (1) RU2688935C2 (fr)
SG (1) SG11201608402WA (fr)
SI (1) SI3139903T1 (fr)
SM (1) SMT201900525T1 (fr)
WO (1) WO2015169728A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201809633T4 (tr) 2014-05-07 2018-07-23 Bristol Myers Squibb Co Diyabet gibi hastalıkların tedavisine yönelik pirolidin GPR40 modülatörleri.
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
FR3039765B1 (fr) * 2015-08-07 2018-08-24 Oreal Procede cosmetique de traitement des matieres keratiniques
CA3000088A1 (fr) * 2015-09-28 2017-04-06 Azura Ophthalmics Ltd. Agents contenant un thiol et un disulfure permettant d'augmenter la secretion lipidique des glandes de meibomius
JP2018532753A (ja) * 2015-10-30 2018-11-08 クロマ−ファーマ ゲゼルシャフト エム．ベー．ハー． 滅菌水性点眼液の治療的使用
CA3001634C (fr) 2015-10-30 2023-05-23 Croma-Pharma Gesellschaft M.B.H. Utilisation therapeutique d'une solution ophtalmique aqueuse sterile
JP7154764B2 (ja) * 2015-12-22 2022-10-18 日油株式会社 涙液油層安定化剤およびこれを含有する点眼剤
AU2017250509B2 (en) 2016-04-14 2023-03-02 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
ES2650981B2 (es) * 2016-07-20 2018-05-04 Ocupharm Diagnostics, Sl Preparación y uso de un extracto de Artemia salina para tratar la superficie ocular
US10618986B2 (en) * 2016-10-19 2020-04-14 Alcon Inc. Hydrophilic copolymer with pendant thiol groups
AR110125A1 (es) 2016-11-07 2019-02-27 Croma Pharma Ges M B H Compuestos poliméricos que liberan sulfuro de hidrógeno
ES2669446B1 (es) * 2016-11-24 2019-03-13 Saiz Manuel Munoz Producto oftálmico
AU2018247122A1 (en) * 2017-03-29 2019-10-10 Azura Ophthalmics Ltd. Agents for increasing meibomian gland lipid secretion
EP3618803A1 (fr) 2017-05-03 2020-03-11 Croma-Pharma GmbH Solution ophtalmique aqueuse stérile contenant du n-(n-acétylcystéinyl)-chitosane pour le traitement de troubles de la cornée non infectieux
KR102472773B1 (ko) * 2018-02-28 2022-11-30 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 및 양이온성 폴리머를 함유하는 안과용 조성물
JP2020075918A (ja) * 2018-11-02 2020-05-21 千寿製薬株式会社 角膜上皮創傷治癒促進用の眼科用組成物
CN109793707B (zh) * 2019-01-30 2022-04-08 温州医科大学 一种透明质酸—n-乙酰半胱氨酸—壳聚糖滴眼液及其制备方法
US20220296485A1 (en) 2019-08-18 2022-09-22 Pmidg, Llc Compositions for sunscreen compounds and methods thereof
TWI848171B (zh) * 2019-08-27 2024-07-11 日商參天製藥股份有限公司 含有迪夸弗索(diquafosol)或其鹽、及聚乙烯吡咯烷酮之水性眼科用組合物
US20210145861A1 (en) * 2019-11-18 2021-05-20 Gregory J. PAMEL Chitosan containing compositions and methods relating to same
WO2021140417A2 (fr) 2020-01-10 2021-07-15 Azura Ophthalmics Ltd. Instructions pour composition et sensibilité
CN114848670B (zh) * 2022-05-26 2023-06-02 青岛博益特生物材料股份有限公司 一种滴眼液及其制备方法
US20240226180A1 (en) * 2023-01-11 2024-07-11 MAM Holdings of West Florida, L.L.C. Methods and compositions for treating dry eye, tear hyperosmolarity, and other ocular conditions
US20240330778A1 (en) * 2023-04-03 2024-10-03 Halliburton Energy Services, Inc. Borehole holdup prediction using machine learning and pulsed neutron logging tool data

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1258781B (it) 1992-01-16 1996-02-29 Zambon Spa Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol
FR2692582B1 (fr) 1992-06-18 1998-09-18 Flamel Tech Sa Nouveaux derives reticulables de collagene, leur procede d'obtention et leur application a la preparation de biomateriaux.
WO1996031195A1 (fr) * 1995-04-04 1996-10-10 Otsuka Pharmaceutical Co., Ltd. Emballage contenant une formulation de solution aqueuse de chlorhydrate de procaterol et formulation de solution aqueuse de chlorhydrate de procaterol
EP0938896A1 (fr) * 1998-01-15 1999-09-01 Novartis AG Compositions pharmaceutiques autoclavables contenant des agents de chelation
AT406054B (de) 1998-11-04 2000-02-25 Andreas Bernkop-Schnuerch Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung
JP2000302803A (ja) 1999-04-22 2000-10-31 Noevir Co Ltd アミノ酸及びペプチドにより遊離アミノ基が選択的に置換され、実質的に水酸基の置換のない部分脱アセチル化キチン・キトサン誘導体、及びその製造方法
ITRM20010438A1 (it) * 2001-07-23 2003-01-23 Farmigea Spa Preparato oftalmico a base di n-acetilcisteina per il trattamento della sindrome dell'occhio secco.
WO2008052037A2 (fr) * 2006-10-24 2008-05-02 Alcon Research, Ltd. Matériaux d'emballage pour les formulations contenant des dérivés de 2-pyrrolidone
SI2107913T1 (sl) * 2006-12-22 2012-05-31 Croma Pharma Ges M B H Uporaba tioliranih polisaharidov za tkivno avgmentacijo
WO2008094675A2 (fr) 2007-01-31 2008-08-07 Photobiomed Corporation Nouveaux biomatériaux et leurs procédés de production et d'utilisation
US9452592B2 (en) 2007-08-28 2016-09-27 Cryovac, Inc. Multilayer film having an active oxygen barrier layer with radiation enhanced active barrier properties
EP2310002B1 (fr) 2008-04-24 2016-11-02 Medtronic, Inc Gel protecteur à base de chitosane et de polysaccharide oxydé
US20090269417A1 (en) 2008-04-24 2009-10-29 Medtronic, Inc. Thiolated chitosan gel
EP2296637B1 (fr) 2008-04-24 2014-04-02 Medtronic, Inc Composition protectrice contenant du chitosane

Also Published As

Publication number Publication date
US10653620B2 (en) 2020-05-19
BR112016024454B1 (pt) 2023-03-07
CN106456536A (zh) 2017-02-22
MX377727B (es) 2025-03-11
CN106456536B (zh) 2020-05-12
CL2016002815A1 (es) 2017-05-12
KR20170030471A (ko) 2017-03-17
US20170224614A1 (en) 2017-08-10
AU2015257874A1 (en) 2016-10-20
RU2016143341A (ru) 2018-06-07
JP2017514916A (ja) 2017-06-08
RU2016143341A3 (fr) 2018-12-25
HUE046425T2 (hu) 2020-02-28
EP3139903B1 (fr) 2019-07-03
SI3139903T1 (sl) 2019-10-30
RU2688935C2 (ru) 2019-05-23
US20190269613A1 (en) 2019-09-05
BR112016024454A2 (pt) 2017-08-15
CA2947065C (fr) 2022-04-19
RS59383B1 (sr) 2019-11-29
SMT201900525T1 (it) 2019-11-13
PL3139903T3 (pl) 2019-12-31
PT3139903T (pt) 2019-10-24
AR100334A1 (es) 2016-09-28
WO2015169728A1 (fr) 2015-11-12
EP3139903A1 (fr) 2017-03-15
CY1122122T1 (el) 2020-11-25
MX2016013710A (es) 2017-03-31
US10342759B2 (en) 2019-07-09
KR102378391B1 (ko) 2022-03-24
AU2015257874B2 (en) 2019-11-28
IL248804B (en) 2020-05-31
ES2747808T3 (es) 2020-03-11
HRP20191667T1 (hr) 2019-12-13
SG11201608402WA (en) 2016-11-29
LT3139903T (lt) 2019-09-10
MA39767A (fr) 2015-11-12
JP6639480B2 (ja) 2020-02-05
CA2947065A1 (fr) 2015-11-12
BR112016024454A8 (pt) 2021-06-29
ME03505B (fr) 2020-04-20
IL248804A0 (en) 2017-01-31
DK3139903T3 (da) 2019-09-09

Similar Documents

Publication Publication Date Title
MA39767A (fr) Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'oeil sec
EP4374851A3 (fr) Composition ophtalmique pour le traitement d'une maladie de l' il sec
MY166228A (en) Compositions comprising mixtures of semifluorinated alkanes
MA43113A (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
EA201890111A1 (ru) Замещенные производные оксопиридина
MY198587A (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MA39359A1 (fr) Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés
EA201692008A1 (ru) Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
EA201692031A1 (ru) Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций
MX2016010173A (es) Metodos de tratamiento de enfermedad de alzheimer.
MA49947B1 (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
EA201992175A1 (ru) Композиции и способы, включающие пробиотические молекулы
MA42016A1 (fr) Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
BR112021014566A2 (pt) Moduladores de gpr35
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
EA202192183A1 (ru) Композиции, обладающие активностью удаления липофусцина из клеток сетчатки
EP4636078A3 (fr) Kit de préparation d'un agent de traitement de maladie, agent de traitement de maladie et procédé de préparation d'un agent de traitement de maladie
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EA201892389A1 (ru) Офтальмологическая композиция, содержащая синергическую комбинацию гликогена и гиалуроновой кислоты или ее соли
MA40915B1 (fr) Composition pharmaceutique comprenant le bisoprolol et le périndopril
AR106493A1 (es) Uso terapéutico de una solución oftálmica acuosa estéril
WO2017205779A3 (fr) Compositions et méthodes de traitement des troubles liés à l'activité de l'inflammasome et à l'expression de l'il-1alpha